Isaac Jenabi, MD
Interventional Pain Medicine · Torrance, CANPI 1649698218
Payments from drug & device makers
Across 42 payments — averaging $135.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$1K
- Boston Scientific$163
- Nevro Corp.$153
- Collegium Pharmaceutical, Inc.$78
- SPR Therapeutics, Inc$56
- plus $141 from 6 others
What the payments were for
- Grants$3,75066%
- Travel & lodging$4909%
- Food & beverage$1,43225%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $3,750 |
| Abbott | 25 | $1,331 |
| Boston Scientific | 2 | $163 |
| Nevro Corp. | 2 | $153 |
| Collegium Pharmaceutical, Inc. | 5 | $78 |
| SPR Therapeutics, Inc | 1 | $56 |
| Vertex | 1 | $34 |
| Nalu Medical, Inc. | 1 | $30 |
| Curonix LLC | 1 | $26 |
| Bioventus LLC | 1 | $23 |
| West Therapeutics Development, LLC | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,672 in reported general payments places this provider in the 60th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 182 | $19,383 |
| Pregabalin | 131 | $2,921 |
| Gabapentin | 239 | $2,113 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 115 | $2,068 |
| Methocarbamol | 124 | $1,035 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $822 |
| Celecoxib | 46 | $673 |
| Tizanidine Hcl | 41 | $463 |
| Duloxetine Hcl | 26 | $314 |
| Tramadol Hcl | 71 | $159 |
| Baclofen | 17 | $122 |
| Methylprednisolone | 18 | $93 |
| Meloxicam | 90 | $90 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Torrance
- Munish LalTorrance$7K
- Sheldon JordanSanta Monica$3.1M
- Ezekiel FinkBeverly Hills$2.3M
- Matthew DotyOroville$1.3M
- Tim LeierRancho Mirage$749K
- Pragya GuptaEscondido$647K
- Michael Verdolinla Mesa$563K
- Standiford HelmOrange$476K
- Patrick BuchananCamarillo$453K
- Roy BrownlowSan Diego$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.